Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Allergan

Approvalsdevice change approved (PMA)4 Nov 2026

Allergan

4 Nov 2026: Device change approved (PMA) · Juvéderm Ultra XC; Juvéderm Ultra Plus XC. Recorded in the openFDA device PMA data.

View the source record

Decided
4 Nov 2026
Device
Juvéderm Ultra XC; Juvéderm Ultra Plus XC
Specialty
General, Plastic Surgery
Type
Supplement (Normal 180 Day Track)
Reason
Change Design/Components/Specifications/Material
Reference
P050047 S106
Location
Irvine, CA
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Allergan

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Allergan in our registers.

More in General, Plastic Surgery

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.